statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xilio Therapeutics reports Q4 results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...

12 titoli sanitari in movimento, sessione regolare del 01/04/2024

Titoli in rialzo
Le azioni di Sunshine Biopharma (NASDAQ:SBFM) hanno fatto segnare +84,29% a 0,11 dollari durante la sessione regolare di luned .
Le azioni di Xilio Therapeutics (NASDAQ:XLO) sono...

12 acciones de salud en movimiento en la sesi n intrad a del 01/04/2024

Acciones al alza
Sunshine Biopharma (NASDAQ:SBFM) se anotaron un alza del 93,22% para establecerse en los 0,12 d lares durante la sesi n del regular del lunes.
Xilio Therapeutics (NASDAQ:XLO) ganaron...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

12 titoli sanitari in movimento, pre-market del 29/03/2024

Titoli in rialzo
Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd .
Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...

Xilio Therapeutics announces $11.3M private placement equity financing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4...

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilios Phase 1 tumor-activated IL-12...

-- Gilead Granted Exclusive License to Xilio's Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY...

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Volume	88,769.00
52-Wk High	$2.94
52-Wk Low	$0.49

XLO Xilio Therapeutics Inc

About

Feed

News

Fundamentals